Rhythm Pharmaceuticals closed up 28% on November 4, 2026 after the Wall Street Journal reported a $10 billion, $124 per share takeover offer from AstraZeneca.
Last updated: November 5, 2026
The Wall Street Journal reported that AstraZeneca offered $10 billion, or $124 per share, for Rhythm Pharmaceuticals last month. Rhythm closed November 4 at $110.68, up 28.0%, on a day healthcare led the market after the midterm elections.
This report covers Wednesday, November 4, 2026: the Rhythm bid report, the post election healthcare session, Novo Nordisk’s third quarter, Lonza’s purchase of five Merck KGaA sites, and the TCT datasets moving toward labels.
What did the Wall Street Journal report about AstraZeneca’s offer for Rhythm Pharmaceuticals?
Per coverage of the Journal’s report, AstraZeneca made a $10 billion acquisition offer for Rhythm Pharmaceuticals last month at $124 per share, after previously expressing interest. Neither company’s comment appears in the coverage, and the report does not say whether talks are continuing.
The report was carried November 4 by Investing.com and Yahoo Finance, which attribute it to people familiar with the matter cited by the Journal. The stated logic is rare disease: Rhythm sells IMCIVREE (setmelanotide) for rare genetic obesity disorders and reported $92.1 million of third quarter revenue on Monday, up 29% sequentially. The offer, as reported, was made in October, which means it predates this week’s news: the LG Chem royalty amendment, the up to $750 million KKR HealthCare Royalty and Blackstone credit facility, and Tuesday’s 7.5% decline on the quarter itself.
| The reported offer against the tape | Figure |
|---|---|
| Reported offer (per the WSJ, made last month) | $124 per share, about $10 billion |
| Tuesday close, November 3, before the report | $86.44, after a 7.5% drop on its own Q3 |
| Wednesday close, November 4 | $110.68, up 28.0% (our arithmetic) |
| Gap from Wednesday close to reported offer | About 12% (our arithmetic) |
| Status of talks | Not stated in the report |
Two more Rhythm items landed the same week and frame what a buyer would be acquiring. The company begins a pivotal Phase 3 of bivamelagon, its oral MC4R agonist, in acquired hypothalamic obesity by year end, and presents final Phase 3 data for setmelanotide in that indication at ObesityWeek, November 14 to 17. On Wednesday, NICE also updated its IMCIVREE guidance to include adults living with Bardet Biedl syndrome, per the company’s release. One caution for readers: the offer figures come from a single reported source, no company has confirmed them, and reported approaches sometimes end without a transaction.
Why did healthcare stocks rally after the 2026 midterm elections?
Reuters reported that Democrats swept the Senate and the House, and that health insurers and hospital chains rallied on hopes of delayed Medicaid cuts and restored enhanced ACA subsidies. Medtech led the large caps, with Stryker up 9.4% and Medtronic up 6.1% by our math.
The mechanism, per the Reuters report, runs through coverage: analysts at Bernstein said a Democratic Congress could delay provisions of the budget law that reduce Medicaid enrollment and constrain state directed payments, and could improve the odds of extending the enhanced ACA premium subsidies that expired at the start of this year. Centene rose more than 8% and HCA, Tenet and Universal Health Services gained 6 to 8% in early trading, per the same report. J.P. Morgan offered the caveat that major policy changes remain unlikely against a presidential veto.
Pharmaceutical executives, for their part, treated the result as largely priced in. BioSpace reported from this week’s earnings calls that most favored nation pricing is now embedded: Novo Nordisk chief executive Mike Doustdar said “There’s always been a strong bipartisan support from both sides of the aisle for what we do,” Pfizer’s Albert Bourla said he expects no changes to the MFN deals this year, and Leerink Partners wrote that Democrats have “bigger fish to fry” near term, while flagging likely investigations into how the MFN deals were negotiated and renegotiation risk in 2028, when the voluntary tariff avoidance agreements expire.
What did Novo Nordisk report in its third quarter 2026 results?
Per pharmaphorum, Novo Nordisk’s group sales rose 4% to DKK 79.2 billion in the third quarter, oral Wegovy recorded DKK 5.39 billion (about $813 million), and the company now expects full year sales and operating profit within 2% of 2025 levels, which the outlet characterizes as an improvement on its earlier outlook.
The product mix tells the story. Injectable Wegovy declined 2% to DKK 20.4 billion and Ozempic fell 5% to DKK 29.7 billion, while the Wegovy pill, sold so far in the US, UAE, UK and Germany, posted its DKK 5.39 billion in its first full quarter. The same report puts Eli Lilly’s rival oral, Foundayo (orforglipron), at $184 million for the same period. Chief executive Mike Doustdar said he was “particularly pleased to see both US operations and international operations deliver sales growth this quarter.” On the pipeline, per pharmaphorum: a US FDA decision on CagriSema is expected before year end with a launch planned for early 2027, the oral candidate zenagamtide (formerly amycretin) has entered Phase 3 in the AMAZE 9 trial, and Frehemgo (denecimig) received an EU positive opinion in haemophilia A.
A sourcing note: Novo Nordisk’s Form 6-K with the results was filed with the SEC on November 4, which we confirmed on the EDGAR filing index, but the three megabyte exhibit could not be retrieved by our tools tonight. Every figure in this section is therefore attributed to pharmaphorum’s November 4 report rather than quoted from the company announcement, and we will reconcile against the primary document. Novo’s US ADR closed at $42.18, up 5.0% by our math, on the sector’s strongest day in months.
What is Lonza buying from Merck KGaA?
Lonza agreed to acquire five US manufacturing sites from Merck KGaA, Darmstadt, Germany, taking its US CDMO network from four to nine sites. About 1,100 employees transfer, closing is expected mid 2027, and Lonza puts the enterprise value in the low to mid triple digit millions of Swiss francs.
The deal was announced Tuesday, November 3 (our Tuesday night report missed it, so it appears here a day late). Per Lonza’s release, the sites map to specific modalities:
| Site | What it makes |
|---|---|
| St. Louis, Missouri | Bioconjugates |
| Madison and Verona, Wisconsin | High potency payload linkers for ADCs |
| Carlsbad, California | Viral vectors, including aseptic fill finish |
| Indianapolis, Indiana | Lipid nanoparticles, liposomes and PEGylated proteins, including aseptic fill finish |
The purchase is in cash, keeps Lonza’s BBB+ rating, and is expected to contribute around CHF 250 million in sales in 2028 at a CORE EBITDA margin below group level, reaching group margin by the mid 2030s. On the analyst call, per BioSpace, chief executive Wolfgang Wienand pointed to the middle of a CHF 100 million to CHF 600 million range as “roundabout the right view” on price and said capacity utilization at the sites is “way below” what he believes is achievable; BioSpace also reports his estimate that the bioconjugation market grows from about $30 billion today to about $110 billion by 2033. Merck KGaA group chief executive Kai Beckmann framed the sale as portfolio concentration: “A more concentrated Life Science portfolio will allow us to focus our investments on building our scientific leadership.” For Lonza the move extends the US expansion that began with the Vacaville biologics purchase and the Bend, Oregon investment, and points it at ADC payloads and gene therapy capacity.
What did Medtronic’s SPYRAL AFFIRM study show at TCT 2026?
Per Medtronic’s Tuesday release, the SPYRAL AFFIRM post approval study of the Symplicity Spyral renal denervation system met its six month endpoints, showing statistically significant office, home and 24 hour ambulatory blood pressure reductions without increased medications, and the FDA approved a label update adding the data.
The 594 patient US cohort was notable for its breadth: 45% women, 27% Black and 11% Hispanic patients, with results published in Circulation: Cardiovascular Interventions. Per MedTech Dive’s conference wrap, nearly nine in ten patients achieved an office systolic reduction of at least 10 mmHg, a home reduction of at least 5 mmHg, and at least one fewer antihypertensive medication. Two other TCT datasets matter for labels. Edwards’ PROGRESS trial, published in NEJM, showed TAVR was superior to clinical surveillance in moderate aortic stenosis on death or heart failure events at two years, 16.7% versus 23.9%, in 744 patients, though all cause mortality ran numerically higher with TAVR, 8.4% versus 7.3%, a detail analysts flagged. Abbott’s Amulet 360 left atrial appendage device showed 96.3% complete closure at one year with a 1.8% ischemic stroke or systemic embolism rate in VERITAS, and remains under FDA review. Medtronic’s stock closed up 6.1% on Wednesday; the move came a day after the data and inside the post election rally, so we assign it no single cause.
How did Amgen’s first reaction session grade the week’s through line?
Amgen closed up 3.7% at $478.48 in the first session after its third quarter beat, the first major this earnings season to clear higher after good results. The grade carries an asterisk: the entire sector rallied on the election result the same day.
We have tracked a market that sells majors on beats, as Johnson & Johnson and Pfizer both demonstrated, so a positive first reaction to Amgen’s 8% revenue growth and 14% EPS growth would ordinarily be the week’s cleanest counterexample. On a day when Stryker rose 9.4% and the S&P 500 rose 1.7%, the signal cannot be separated from the policy move. Pfizer, for its part, recovered 2.6% to $30.79 in its second session after Tuesday’s decline on raised guidance. The through line gets its real test when the tape normalizes, and Friday’s edition will grade the week in full.
Where does Karyopharm’s Chapter 11 stand after three sessions?
Karyopharm’s shares fell another 17.4% to $0.0729 on Wednesday, down about 89% from Friday’s close by our math. The interim court orders expected early this week could not be verified tonight, and the day 74 FDA letter on the selinexor myelofibrosis filing is expected around November 10.
The company filed Chapter 11 on November 2 in the Southern District of Texas with Ayrmid as stalking horse bidder, under a plan that hands creditors 55% of the merged company and cancels existing shares with no distribution. Our checks of the SEC’s filing browser and the claims agent’s docket were both refused tonight, so whether the first day hearings produced interim debtor in possession and bidding procedure orders remains unconfirmed; we will keep checking. The sequencing to watch is unchanged: the day 74 letter around November 10 lands before the November 30 voting deadline and the combined hearing requested for about January 11, 2027.
Which stocks moved on November 4, 2026?
Settled closes from exchange data; percentage moves are our arithmetic against Tuesday’s closes.
| Ticker | Nov 4 close | Move | Context |
|---|---|---|---|
| RYTM | $110.68 | +28.0% | WSJ reported a $10B, $124 per share AstraZeneca offer |
| SYK | $339.65 | +9.4% | Led large cap medtech in the post election rally |
| MDT | $104.96 | +6.1% | Sector day, one day after SPYRAL AFFIRM data and a label update; no single cause assigned |
| NVO (ADR) | $42.18 | +5.0% | Q3 results and an improved outlook, per pharmaphorum |
| AMGN | $478.48 | +3.7% | First reaction to the Q3 beat, confounded by the rally |
| KPTI | $0.0729 | −17.4% | Third session after the Chapter 11 filing |
Context: XBI closed at $159.10, up 2.7%, and SPY at $766.81, up 1.7%. Against the rally, Regeneron fell 4.4% and Illumina 4.9%; we could not date Regeneron’s third quarter release tonight, so we assign no cause to either move and will revisit both.
Frequently asked questions
Did AstraZeneca or Rhythm confirm the takeover offer?
No. The figures come from the Wall Street Journal’s reporting, as carried by Investing.com and Yahoo Finance on November 4. No comment from either company appears in that coverage, and neither company has issued a release about it.
How much did AstraZeneca reportedly offer for Rhythm Pharmaceuticals?
$10 billion, or $124 per share, per the Journal’s report. The offer was reportedly made last month, in October 2026.
Is an AstraZeneca acquisition of Rhythm certain to happen?
No. The report does not say whether talks are ongoing, whether the offer was rejected, or whether a deal will occur. Reported approaches sometimes end without a transaction.
Why would AstraZeneca want Rhythm Pharmaceuticals?
The report frames it as rare disease: Rhythm sells IMCIVREE for rare genetic obesity disorders, reported $92.1 million in third quarter revenue, and is moving its oral MC4R agonist bivamelagon into a pivotal Phase 3 in acquired hypothalamic obesity by year end.
What happened to healthcare stocks after the 2026 midterms?
Healthcare led the market in the first post election session. Reuters tied the rally in insurers and hospitals to hopes of delayed Medicaid cuts and restored enhanced ACA subsidies after a Democratic sweep; large cap medtech rose 5 to 9%.
Did the midterm result change most favored nation drug pricing?
Not according to the companies. BioSpace reported executives treating MFN as embedded, with Pfizer expecting no changes this year; Leerink flagged likely congressional investigations near term and renegotiation risk in 2028, when the voluntary tariff agreements expire.
How big was Novo Nordisk’s oral Wegovy quarter?
DKK 5.39 billion, about $813 million, in the third quarter across the US, UAE, UK and Germany, per pharmaphorum. It was the pill’s first full quarter on the market.
How did oral Wegovy compare with Eli Lilly’s Foundayo?
Per pharmaphorum, oral Wegovy’s roughly $813 million compares with $184 million for Foundayo (orforglipron) in the same period, a gap that partly reflects launch timing and brand recognition rather than drug performance alone.
What is Novo Nordisk’s 2026 outlook now?
Per pharmaphorum, Novo expects full year sales and operating profit to be within 2% of 2025 levels, which the outlet characterizes as an improvement on earlier forecasts. We could not retrieve the company announcement’s verbatim ranges tonight.
Which sites is Lonza buying from Merck KGaA, and for how much?
Five US sites: St. Louis (bioconjugates), Madison and Verona (payload linkers), Carlsbad (viral vectors) and Indianapolis (lipid nanoparticles and fill finish). Lonza puts the enterprise value in the low to mid triple digit millions of Swiss francs, paid in cash, closing mid 2027.
What did Medtronic’s SPYRAL AFFIRM study show?
In 594 US patients, the Symplicity Spyral system produced statistically significant office, home and 24 hour ambulatory blood pressure reductions at six months without increased medications, per Medtronic’s release, and the FDA approved a label update adding the data.
What did the Edwards PROGRESS trial show at TCT 2026?
TAVR was superior to clinical surveillance in moderate aortic stenosis on death or heart failure events at two years, 16.7% versus 23.9%, in 744 patients, per the NEJM publication; all cause mortality was numerically higher with TAVR, 8.4% versus 7.3%.
When is Karyopharm’s day 74 letter due, and why does it matter?
Around November 10. Karyopharm’s own filings call the selinexor myelofibrosis application the principal driver of the value being sold in its Chapter 11, so the letter lands before the November 30 creditor vote and can move the auction.
When does Rhythm present its Phase 3 ObesityWeek data?
ObesityWeek runs November 14 to 17, 2026, and includes final Phase 3 results for setmelanotide in acquired hypothalamic obesity among five Rhythm presentations.
Sources
Primary sources: Lonza press release, November 3, 2026 (lonza.com); Rhythm Pharmaceuticals third quarter 2026 results release, November 3, 2026, and NICE guidance release, November 4, 2026 (ir.rhythmtx.com); Novo Nordisk Form 6-K filed November 4, 2026 (SEC EDGAR filing index; exhibit not retrieved, see sourcing note); Amgen third quarter 2026 release, November 3, 2026 (8-K exhibit); Karyopharm Therapeutics 8-K and exhibits, November 2, 2026 (SEC EDGAR). Market data: exchange settled closes, November 4, 2026; all percentage moves are our arithmetic.
Trade and wire coverage (attributed): Investing.com and Yahoo Finance carrying the Wall Street Journal’s report on the AstraZeneca offer, November 4, 2026; Reuters on the post election healthcare rally, November 4, 2026; pharmaphorum on Novo Nordisk’s third quarter, November 4, 2026; BioSpace on MFN commentary, November 4, 2026, and on the Lonza acquisition, November 3, 2026; MedTech Dive’s TCT 2026 wrap, November 4, 2026; Newsquawk on the SPYRAL AFFIRM release timing, November 3, 2026.
